Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - ciprofloxacin hydrochloride - solution for infusion - 2 mg/ml

United Kingdom - English - myHealthbox

infomed fluids - linezolid - solution for infusion - 2mg/ml - other antibacterials - it is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram-positive bacteria. in determining whether linezolid 2 mg/ml solution for infusion is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among grampositive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms).

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

alkaloid ad skopje - ciprofloxacin - concentrate for solution for infusion - 10mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

anfarm hellas s.a. - ceftriaxone (ceftriaxone sodium) - powder for solution for injection/infusion - 1000mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, escherichia coli, enterobacter aerogenes, proteus mirabilis or serratia marcescens . caused by streptococcus pneumoniae, haemophilus influenzae (including beta-lactamase producing strains) or moraxella catarrhalis (including beta-lactamase producing strains). note: in one study lower clinical cure rates were observed with a single dose of ceftriaxone compared to 10 days of oral therapy. in a second study comparable cure rates were observed between single dose ceftriaxone and the comparator. the potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see clinical studies ). caused by staphylococcus aureus, staphylococcus epidermidis, streptococcus pyogenes , viridans group streptococci, escherichia coli, enterobacter cloacae, klebsiella oxytoca, klebsiella pneumoniae, proteus mirabilis, morganella morganii*, pseudomonas aeruginosa, serratia marcescens, acinetobacter calcoaceticus, bacteroides fragilis * or peptostreptococcus species. caused by escherichia coli, proteus mirabilis, proteus vulgaris, morganella morganii or klebsiella pneumoniae . caused by neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of neisseria gonorrhoeae . caused by neisseria gonorrhoeae . ceftriaxone sodium, like other cephalosporins, has no activity against chlamydia trachomatis . therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. caused by staphylococcus aureus, streptococcus pneumoniae, escherichia coli, haemophilus influenzae or klebsiella pneumoniae . caused by staphylococcus aureus, streptococcus pneumoniae, escherichia coli, proteus mirabilis, klebsiella pneumoniae or enterobacter species. caused by escherichia coli, klebsiella pneumoniae, bacteroides fragilis, clostridium species (note: most strains of clostridium difficile are resistant) or peptostreptococcus species. caused by haemophilus influenzae, neisseria meningitidis or streptococcus pneumoniae . ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by staphylococcus epidermidis * and escherichia coli* . *efficacy for this organism in this organ system was studied in fewer than ten infections. the preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. when administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure. ceftriaxone for injection is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone (see warnings – hypersensitivity reactions ). premature neonates : ceftriaxone for injection is contraindicated in premature neonates up to a post-menstrual age of 41 weeks (gestational age + chronological age). hyperbilirubinemic neonates : hyperbilirubinemic neonates should not be treated with ceftriaxone for injection. ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients. ceftriaxone for injection is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing iv solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see clinical pharmacology, warnings and dosage and administration ). cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium-containing fluids. in some of these cases, the same intravenous infusion line was used for both ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. there have been no similar reports in patients other than neonates. intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated. when lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection, exclude all contraindications to lidocaine. refer to the prescribing information of lidocaine.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - linezolid - solution for infusion - linezolid 2 mg/ml - linezolid - linezolid - therapy is indicated only when an organism resistant to all other antibiotics is suspected. zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (mdrsp). 2) skin and soft tissue infections including diabetic foot infections. 3) enterococcal infections. combination therapy may be indicated if a concomitant gram negative pathogen is documented or suspected.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, ha

United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - ceftizoxime sodium (unii: 26337d5x88) (ceftizoxime - unii:c43c467dpe) - solution - 1 g in 50 ml - cefizox (ceftizoxime injection) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. lower respiratory tract infections caused by klebsiella spp.; proteus mirabilis ; escherichia coli; haemophilus influenzae including ampicillin­resistant strains; staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); serratia spp.; enterobacter spp.; bacteroides spp.; and streptococcus spp. including s. pneumoniae , but excluding enterococci. urinary tract infections caused by staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); escherichia coli ; pseudomonas spp. including p. aeruginosa ; proteus mirabilis ; p. vulgaris ; providencia rettgeri (formerly proteus rettgeri ) and morganella morganii (formerly proteus morganii ); klebsiella spp.; serratia spp. including s. marcescens ; and enterobacter spp. gonorrhea including uncomplicated cervical and urethral gonorrhea caused by neisseria gonorrhoeae . pelvic inflammatory dise

United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - cephapirin sodium (unii: 431lff7i7j) (cephapirin - unii:89b59h32vn) - cephapirin 200 mg in 10 ml - for lactating cows only / for the treatment of bovine mastitis today (cephapirin sodium) for intramammary infusion should be used at the first signs of inflammation or at the first indication of any alteration in the milk. treatment is indicated immediately upon determining, by c.m.t. or other tests, that the leukocyte count is elevated, or that a susceptible pathogen has been cultured from the milk. today for intramammary infusion has been shown to be efficacious in the treatment of mastitis in lactating cows caused by susceptible strains of streptococcus agalactiae and staphylococcus aureus including strains resistant to penicillin. indicaciones Únicamente para vacas lactantes / para el tratamiento de mastitis bovina today (cefapirina sódica) para infusión intramamaria deberá administrarse desde los primeros signos de inflamación o al primer indicio de cualquier alteración de la leche. el tratamiento resulta indicado inmediatamente después de determinar mediante la prueba de california para mastitis (c.m.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - cephapirin benzathine (unii: 90g868409o) (cephapirin - unii:89b59h32vn) - cephapirin 300 mg in 10 ml - for the treatment of mastitis in dairy cows during the dry period. tomorrow has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by streptococcus agalactiae and staphylococcus aureus including penicillin-resistant strains. treatment of the dry cow with tomorrow is indicated in any cow known to harbor any of these organisms in the udder at drying off. indicaciones para el tratamiento de mastitis bovina durante el período seco. extensos estudios clínicos han demostrado que tomorrow es eficaz en el tratamiento de la mastitis en vacas secas, cuando ésta es causada por el streptococcus agalactiae y el staphylococcus aureus, incluyendo cepas resistentes a la penicilina. el tratamiento de la vaca seca con tomorrow es recomendado para cualquier vaca que se sepa alberga a cualquiera de estos organismos en la ubre al momento del período de secado. not for human use. este producto no es para administrarse en humanos.